270 related articles for article (PubMed ID: 22868411)
1. Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.
Nakazawa S; Yokoyama C; Nishimura N; Horisawa T; Kawasaki A; Mizuma H; Doi H; Onoe H
Psychopharmacology (Berl); 2013 Jan; 225(2):329-39. PubMed ID: 22868411
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
[TBL] [Abstract][Full Text] [Related]
3. Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).
Hodé Y; Benyamina A; Arbus C; Reimold M
Psychopharmacology (Berl); 2011 Oct; 217(3):315-21. PubMed ID: 21479533
[TBL] [Abstract][Full Text] [Related]
4. Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects.
Wong DF; Kuwabara H; Brašić JR; Stock T; Maini A; Gean EG; Loebel A
Psychopharmacology (Berl); 2013 Sep; 229(2):245-52. PubMed ID: 23649882
[TBL] [Abstract][Full Text] [Related]
5. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
[TBL] [Abstract][Full Text] [Related]
6. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.
Kessler RM; Ansari MS; Riccardi P; Li R; Jayathilake K; Dawant B; Meltzer HY
Neuropsychopharmacology; 2005 Dec; 30(12):2283-9. PubMed ID: 16123775
[TBL] [Abstract][Full Text] [Related]
7. Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: analysis by [3H]SB-269970 autoradiography.
Horisawa T; Ishiyama T; Ono M; Ishibashi T; Taiji M
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():132-7. PubMed ID: 23367506
[TBL] [Abstract][Full Text] [Related]
8. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.
Lian J; Huang XF; Pai N; Deng C
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047
[TBL] [Abstract][Full Text] [Related]
9. Lurasidone: a new treatment option for schizophrenia.
Owen RT
Drugs Today (Barc); 2011 Nov; 47(11):807-16. PubMed ID: 22146224
[TBL] [Abstract][Full Text] [Related]
10. Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.
Seneca N; Finnema SJ; Laszlovszky I; Kiss B; Horváth A; Pásztor G; Kapás M; Gyertyán I; Farkas S; Innis RB; Halldin C; Gulyás B
Psychopharmacology (Berl); 2011 Dec; 218(3):579-87. PubMed ID: 21625907
[TBL] [Abstract][Full Text] [Related]
11. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
[TBL] [Abstract][Full Text] [Related]
12. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
[TBL] [Abstract][Full Text] [Related]
13. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
14. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.
Yuen EY; Li X; Wei J; Horiguchi M; Meltzer HY; Yan Z
Mol Pharmacol; 2012 Feb; 81(2):113-9. PubMed ID: 22072817
[TBL] [Abstract][Full Text] [Related]
15. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Rollema H; Lu Y; Schmidt AW; Sprouse JS; Zorn SH
Biol Psychiatry; 2000 Aug; 48(3):229-37. PubMed ID: 10924666
[TBL] [Abstract][Full Text] [Related]
16. Effects of lurasidone on executive function in common marmosets.
Murai T; Nakako T; Ikejiri M; Ishiyama T; Taiji M; Ikeda K
Behav Brain Res; 2013 Jun; 246():125-31. PubMed ID: 23454675
[TBL] [Abstract][Full Text] [Related]
17. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
18. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).
Hodé Y; Reimold M; Demazières A; Reischl G; Bayle F; Nuss P; Hameg A; Dib M; Macher JP
Psychopharmacology (Berl); 2005 Jul; 180(2):377-84. PubMed ID: 15948013
[TBL] [Abstract][Full Text] [Related]
19. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature.
Stone JM; Davis JM; Leucht S; Pilowsky LS
Schizophr Bull; 2009 Jul; 35(4):789-97. PubMed ID: 18303092
[TBL] [Abstract][Full Text] [Related]
20. A positron emission tomography occupancy study of brexpiprazole at dopamine D
Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
